2021, Number 4
<< Back Next >>
Med Int Mex 2021; 37 (4)
Refractory malleolar ulcers associated with systemic sclerosis sine scleroderma.
Fernández-del Campo GA, Porras-Méndez CMV, Pérez-Téllez K, Alagón Fernández-del Campo P
Language: Spanish
References: 9
Page: 633-635
PDF size: 217.24 Kb.
ABSTRACT
Background: Malleolar ulcers associated with systemic sclerosis are related to the
microangiopathic affection characteristic of this disease.
Clinical cases: A 57-year-old female patient with maleolar ulcers refractory to conventional
treatment, whose study led to the diagnosis of an underlying cause, systemic
sclerosis sine scleroderma.
Conclusions: In this case, the diagnosis of scleroderma was established due to the
study of resistant malleolar ulcers that, although they have a low incidence of systemic
sclerosis compared to those of the upper limbs, cause greater morbidity and have lesser
response to conventional treatment, for which reason it should be investigated always
an underlying cause and establish individualized treatment.
REFERENCES
Rodnan GP, Benedek TG. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma) Ann Intern Med 1962; 57: 305-19. doi. 10.7326/0003- 4819-57-2-305.
Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthr Res Ther 2003; 5 (2): 80-93. doi. 10.1186/ar628.
Katsumoto T, Whitfield M, Connolly MK. The Pathogenesis of Systemic Sclerosis. Annu Rev Pathol 2011; 6: 509-537. doi. 10.1146/annurev-pathol-011110-130312.
Diab S, Dostrovsky N, Hudson M, Tatibouet S, et al., The Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. J Rheumatol 2014; 41 (11): 2179-2185. doi. 10.3899/ jrheum.140236.
Shanmugam VK, Price P, Attinger CE, Steen VD. Lower extremity ulcers in systemic sclerosis: Features and response to therapy. Int J Rheumatol 2010; 2010:747946. doi. 10.1155/2010/747946.
Koutroumpas A, Ziogas A, Alexiou I, Barouta G, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29 (10): 1167-1168. doi. 10.1007/s10067-010-1498-z.
Volkmann ER, Tashkin DP, Li N, Roth MD, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: An analysis of scleroderma lung studies I and II. Arthr Rheumatol 2017; 69 (7): 1451-1460.
Giuggioli D, Manfredi A, Lumetti F, Colaci M, et al. Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature. Autoimmun Rev 2018; 17 (2): 155-164. doi. 10.1016/j. autrev.2017.11.020.
Bohelay G, Blaise S, Levy P, Claeys A, et al. Lower-limb ulcers in systemic sclerosis: A multicentre retrospective case-control study. Acta Dermatol Venereol 2018; 98 (7): 677-682. doi. 10.2340/00015555-2939.
Full text